Massachusetts is currently home to 3202 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
NCT05734495
Recruiting
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) * Venetoclax (a BCL2 inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Beth Israel Deaconness Medical, Boston, Massachusetts
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
NCT05166161
Recruiting
The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Phenylketonuria
Register for Updates
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Recruiting
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigational combination) * Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia
Register for Updates
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Recruiting
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/07/2025
Locations: Harvard/Mass General/Brigham Hospitals, Boston, Massachusetts
Conditions: Post Operative Surgical Site Infection
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics), Boston, Massachusetts
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
NCT03603730
Recruiting
Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/07/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Dyspepsia, Gastroparesis
Register for Updates
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
Recruiting
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Colonic Neoplasms
Register for Updates
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
NCT06957366
Recruiting
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure involving neuraxial anesthesia. The purpose of the PAUSE 2 study is to show that PAUSE management will be as safe (i.e., non-inferior) as ASRA management, with 95% of patients having low/undetectable pre-operative DOAC levels \<30 ng/mL in each group., at the time of su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Brigham and Woman's Hospital, Boston, Massachusetts
Conditions: Atrial Fibrillation (AF), VTE
Register for Updates
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2025
Locations: Site 22, Brighton, Massachusetts
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060
Recruiting
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lymphoma, T-Cell
Register for Updates
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
NCT06152237
Recruiting
The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is up to 6 years.
Gender:
FEMALE
Ages:
Between 5 years and 8 years
Trial Updated:
05/06/2025
Locations: Boston Children's at Brookline, Boston, Massachusetts
Conditions: Rett Syndrome
Register for Updates
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
NCT06136546
Recruiting
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
Gender:
ALL
Ages:
Between 25 years and 50 years
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Depressive Disorder, Major, Inflammation
Register for Updates